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Abstract
Background: About two thirds of adults suffer from backpain at some time during their life. In
the emergency room many patients with acute back pain are treated with intravenous non-
steroidal analgesics. Whether this treatment is superior to oral administration of non-steroidal
analgesics is unknown. Intravenous administration, however, requires considerable amounts of
resources and accounts for high workload in busy clinics. In the further course centrally acting
muscle relaxants are prescribed but the effectiveness remains unclear. The objective of this study
is on the one hand to compare the effectiveness of intravenous with oral non-steroidal analgesics
for acute treatment and on the other hand to compare the effectiveness of a centrally active muscle
relaxant with placebo given for three days after presentation to the ED (emergency department).
Methods/Design: This study is intended as a randomised controlled factorial trial mainly for two
reasons: (1) the sequence of treatments resembles the actual proceedings in every-day clinical
practice, which is important for the generalisability of the results and (2) this design allows to take
interactions between the two sequential treatment strategies into account. There is a patient
preference arm included because patients preference is an important issue providing valuable
information: (1) it allows to assess the interaction between desired treatment and outcome, (2)
results can be extrapolated to a wider group while (3) conserving the advantages of a fully
randomised controlled trial.
Conclusion: We hope to shed more light on the effectiveness of treatment modalities available
for acute low back pain.
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Background
The estimated prevalence of back pain in the Viennese
population is about 12% [1]. Accordingly, a recent com-
prehensive review article reports that about two thirds of
adults suffer from low back pain and back pain at some
time. This makes back pain one of the most frequent
symptoms why physicians are consulted, surpassed only
by respiratory symptoms [2].
About 30 patients present to our emergency department
every week because of acute low back pain and many of
these are treated with intravenous non-steroidal analge-
sics. Whether this treatment is superior to oral adminis-
tration non-steroidal analgesics is unknown.
Intravenous administration, however, requires consider-
able amounts of resources and accounts for high work-
load in busy clinics.
In the further course non-steriodal analgesics are usually
prescribed, often together with centrally active muscle
relaxants. There is evidence of a possible beneficial ef-
fect, but the quality of the existing studies is poor [3]. Ac-
cordingly, some specialists say that the effectiveness of
centrally active muscle relaxants is unclear [2].
Objectives of the study
1) To compare the effectiveness of intravenous non-ster-
oidal analgesics with oral non-steroidal analgesics for
acute treatment in the emergency department (Stage 1)
2) To compare the effectiveness of either arm with the ef-
fectiveness in those patients who refused to be ran-
domised but agreed to participate in the patient
preference trial with the treatment of their choice
3) To compare the effectiveness of a centrally active mus-
cle relaxant with placebo given for three days after pres-
entation to the ED (Stage 2)
4) To compare the effectiveness of either arm with the ef-
fectiveness in those patients who refused to be ran-
domised but agreed to participate in the patient
preference trial with the treatment of their choice
Methods/Design
This study is intended as a randomised controlled facto-
rial trial mainly for two reasons: (1) the sequence of
treatments resembles the actual proceedings in every-
day clinical practice, which is important for the general-
isability of the resultsand (2) this design allows to take
interactions between the two sequential treatment strat-
egies into account. The patient preference arm is includ-
ed because patients preference is an important issue
providing valuable information: (1) it allows to assess the
interaction between desired treatment and outcome, (2)
results can be extrapolated to a wider group while (3)
conserving the advantages of a fully randomised control-
led trial [4].
Study population
Patients with acute low back pain attending the emer-
gency department of the Vienna General Hospital, a
2000-bed teaching hospital. The emergency department
has a busy outpatient unit with ten rooms for use by gen-
eral internists, neurologists, surgeons, orthopaedics,
dermatologists, jaw surgeons, gynaecologists, ophthal-
mologists and ear-nose-throat physicians [5]. Each year,
about 70 000 patients attend the emergency depart-
ment, of which 30 are treated for acute low back pain
every week.
It is well known that a precise anatomical diagnosis is
difficult and often not possible. Therefore we aim for a
pragmatic approach which is intended (1) to rule out sys-
temic disease, such as neoplasm, infection and inflam-
matory arthritis, accounting for about 3% of the cases [1]
and (2) to detect neurological compromise that may re-
quire neuro-surgical evaluation/intervention. It is gen-
erally advised not to perform any form of imaging if non
of our exclusion criteria (see below) is present [6].
Inclusion criteria
• lower back pain localised between 12th rib and gluteal
fold
• duration of pain of the current period < 7 days
• attending the Department of Emergency Medicine at
the Vienna General Hospital because of low back pain
• agree to be randomised or agree to be included in the
patient preference trial
• written informed consent
Exclusion criteria
• History:
- ingestion of any analgesic drug within 6 hours
- direct impact trauma
- history of cancer
- unexplained weight loss (> 10 kg within 3 months)
- current injection drug use
- any known chronic infection, such as Hepatitis, HIV
(Human Immuno-deficiency Virus), tuberculosisBMC Emergency Medicine 2001, 1:2 http://www.biomedcentral.com/1471-227X/1/2
- immunosuppressive therapy (such as systemic corti-
costeroids, ciclosporine, or such)
- organ transplantation
- history of inflammatory arthritis of large joints
- current bowel or bladder dysfunction
- involved in litigation
- alcohol abuse
- age <19 and > 65 years
- current abdominal problems (epigastric pain)
- a history of gastric or duodenal ulcer
- a history of severe renal or hepatic insufficiency or se-
vere coronary insufficiency.




- sensory or motor deficit in lower limb
- Lasegue positive >60° [7]
- Pregnancy: to be ruled out by a commercially available
and routinely used urine pregnancy test (DIPRO hCG-
CARD®, Dipro Diagnostic Products, Ebreichsdorf, Aus-
tria)
- Urinary tact infection: to be ruled out by a commercially
available and routinely used urine dip stick test (COM-
BUR 9-Test®, Roche, Mannheim, Germany); infection is
assumed if nitrite and leukocytes test positive
• Communication problems:
- Patients who appear not to be able to understand the in-
formation provided to give informed consent for partici-
pation in this trial because of mental or physical
handicaps. It is the duty of the enrolling physician to de-
cide whether a potential participant has sufficient lan-
guage skills to understand the information provided or to
communicate that she/he understands.
- Patients who appear not to be able to understand the in-
formation provided to give informed consent for partici-
pation in this trial because of language barriers. Those
who need an interpreter to communicate with the treat-
ing physician are certainly ineligible. Otherwise it is the
duty of the enrolling physician to decide whether a po-
tential participant has sufficient language skills to under-
stand the information provided.
Ethical approval
The study will be performed in accordance with the Dec-
laration of Helsinki (1964), including current revisions,
the Austrian ,,Arzneimittelgesetz" (1994) and the GCP
guidelines of the European Commission. The protocol
was approved by the ethics committee of the Vienna
Medical Faculty. Depending on the form of consent pa-
tients will be enrolled in the randomised trial or the pa-
tient preference arm.
Planned intervention and timing (figure 1)
After consent and enrolment patients are randomised to
the stage one intervention.
Stage 1 intervention
Patients are randomised to oral diclofenac (150 mg) plus
intravenous placebo or oral placebo plus intravenous di-
clofenac (75 mg) in a double blind fashion. The dose of
diclofenac for oral administration has to be twice the in-
travenous dose because of a 50% first pass elimination of
the active ingredient. Patients will be assessed immedi-
ately before and 90 min after treatment (this is the aver-
age time needed for the intravenous administration of an
infusion containing analgesics). The primary endpoint at
90 minutes is pain assessed with a visual analogue scale
(VAS) [8], secondary endpoint is the Roland Morris dis-
ability questionnaire (RMDQ) [9], and the quality of life
score as measured by the short form 36 (SF-36) [10]. If
patients still have severe pain further intravenous thera-
py should be given according to the discretion of the
treating physician. Patients who refuse randomisation
but agree to participate in the patient preference trial will
receive the treatment of their choice. Treatment and fol-
low-up will be identical in the randomised and patient
preference groups.
Stage 2 intervention
After the first step patients are randomised to oral di-
clofenac (2 ×  100 mg per day or 1 ×  100 mg per day if bod-
yweight is <60 kg) and the oral muscle-relaxant tizanidin
(Sirdalud® 3 ×  2 mg, Novartis Pharma AG, Basel, Swit-
zerland) over 3 days versus oral diclofenac (2 ×  100 mg
per day or 1 ×  100 mg per day if bodyweight is <60 kg)
plus oral placebo in a double blind fashion. Patients with
a history of gastric pain, suggestive of ulcer or non-ulcer
dyspeptic disease will receive a proton pump inhibitor
for gastric protection (pantoprazol 1 ×  40 mg per day,
Pantoloc® Byk Pharma Österreich).BMC Emergency Medicine 2001, 1:2 http://www.biomedcentral.com/1471-227X/1/2
As in the first step, patients who refuse randomisation
but agree to participate in the patient preference trial will
receive the treatment of their choice. Treatment and fol-
low-up will be identical in the randomised and patient
preference groups.
Sample size
Based on a clinically relevant difference of 10 mm ± 20
mm in the visual analogue scale the projected sample
size at a two-sided p-value of 0.02 and a power of 0.85 is
92 per group. This effect size is an estimate based on the
outcome of pain measurement 60 minutes after the oral
administration of a non-steroidal analgesic and a COX-2
inhibitor in patients with chronic low back pain. [11] We
do not assume a relevant attrition rate for phase 1.
Taking a 20% attrition rate over the next 4 days into ac-
count the projected sample size is 115 per group to relia-
bly detect such a difference at the end of phase 2.
Sample size estimations are based on sample size tables
for clinical studies [12].
Statistical analysis
We intend to use two models: (1) a model containing only
randomised patients and (2) a model containing ran-
domised patients and patients in the patient preference
arms. Data will be analysed in an intention-to-treat fash-
ion if patients receive a treatment other than the allocat-
ed treatment For group comparison of continuous data
in model 1 (randomised patients only) either a two tailed
t-test, and an analysis of covariance to adjust for baseline
values in the VAS, or, in case of a non-normal distribu-
Figure 1
Patient flow. Planned interventions and timing of interventions; po indicates enteral (peroral) administration, iv indicates intra-
venous administrationBMC Emergency Medicine 2001, 1:2 http://www.biomedcentral.com/1471-227X/1/2
tion, or ordinal data (RMDQ, SF-36), the Mann-Whitney
U-Test will be used. For model 2 (randomised patients
and patients with preferred treatment) multiple linear
regression will be used to account for baseline differenc-
es and the randomisation status [4]. Stata version 7 (Sta-
ta Corporation, TX, USA) will be used for data analysis.
A p-value < 0.05 is assumed to indicate evidence against
the null hypothesis.
We believe that it is not necessary to define stopping
rules as the observational period is very short and we do
not expect that any treatment, which is already widely
used, will result in increased mortality or disability.
Assignment
Unit of randomisation and method to generate allocation (for both 
stages)
The unit of randomisation is the individual patient.
Blockwise randomisation in blocks of 4 is intended to
achieve intervention and control groups of equal size
[13]. Allocation will be performed using computer pro-
gramme (Machin D, Campbell MJ. Sampsize V2.0 1997)
[12].
Timing of allocation and concealment of allocation
Immediately after consent to participate and enrolment
a consecutively numbered, opaque and sealed envelope
containing an allocation number (see below) will be
opened. Treatment (oral v intravenous diclofenac) will
commence immediately afterwards. For the second stage
of the trial patients will be randomised to a centrally ac-
tive muscle relaxant or placebo. Both groups should re-
ceive a long acting non-steroidal analgesic (diclofenac 2
×  100 mg po) and will be evaluated after 4 days. Ran-
domisation and allocation again will be performed as de-
scribed above with opaque, sealed envelopes.
Method to separate generator from executor
The randomisation will be prepared by a person not in-




This trial is intended to be double blind. Patients, doctors
and outcome assessors are blinded to the nature of the
intervention. Each patient is to receive a pre-prepared
intravenous administration of 250 ml NaCI 0.9% con-
taining either 75 mg diclofenac or placebo of equal ap-
pearance. At the same time patients will receive a capsule
containing 150 mg diclofenac or placebo. The placebo
capsule contains lactose powder and has the same size,
colour and taste as the active drug.
Stage 2
The second stage is also intended as a double blind trial.
Both groups will receive oral diclofenac (Dolpasse®, Fre-
senius, 2 ×  100 mg) for 3 days. Patients are randomised
either to placebo 3 ×  1 for 3 days or oral tizanidin (Sirda-
lud® 3 ×  2 mg) 3 ×  1 for 3 days. The placebo capsule con-
tains lactose powder and has the same size, colour and
taste as the active drug.
Was blinding successful?
To assess whether blinding was successful we will ask pa-
tients and outcome assessors whether the patient re-
ceived active enteral or parenteral treatment (Stage 1).
The question intended for the patient, and the outcome
assessor alike, is: "Do you think the active treatment was
the infusion or the capsule?" Possible answers are: "Most
likely in the infusion."; "Don't know."; "Most likely in the
capsule." For stage 2 we will ask the patient and the out-
come assessor: "Do you think you received the active
treatment or the inactive treatment?" Possible answers
are: "Most likely yes."; "Don't know."; "Most likely no."
Baseline measurements
We intend to assess following baseline parameters be-
sides the clinical symptoms leading to inclusion in the
study and the outcome parameters: age, gender, highest
education.
Primary and secondary outcome measures
For both stages the primary outcome measure is the pain
assessed by means of the VAS [8]. Patients receive an A4
sheet with a 10 cm bold line in the centre which is has "no
pain" above the left end of the line and "pain as bad as
you have ever experienced" at the right end of the line.
Patients are advised to set a marker at the applicable
range with a pencil. The distance of the marker from "no
pain" (=0) will be measured and expressed in mm (max-
imum = 100). For stage one, the visual analogue scale is
evaluated immediately before and 90 min after treat-
ment, for stage two, the VAS is evaluated on day 4
(=three days after enrolment). Patients will be advised to
fill out the scale at home and return the original sheet by
a prepaid return postage envelope.
For both stages the RMDQ [9] and the SF-36 [10] are
employed in an adapted form for secondary outcome
measurements. The Roland Morris disability question-
naire [14] is used in the cross cultural adapted and vali-
dated form for German-speaking patients [10]. The
questionnaire is a questionnaire with 24 items that re-
flect varied activities of daily living due to back pain. An
item receives a score of 1 if it is checked as applicable by
the patient and a score of 0 if not marked. Accordingly
scores can vary from 0 (no disability) to 24 (severe disa-
bility).BMC Emergency Medicine 2001, 1:2 http://www.biomedcentral.com/1471-227X/1/2
The SF-36 is used in the cross cultural adapted and vali-
dated form for German-speaking patients [10]. We se-
lected the items 1 (general health perception), 2 (change
in health), 4 (role limitations (physical problems)), 5
(role limitations (emotional problems)), 9 (vitality) and
10 (social functioning). The score will be calculated ac-
cording to the test-manual
The RMDQ and the SF 36 is evaluated immediately be-
fore treatment (stage 1) by personal interview, then, for
stage two, the RMDQ and the SF 36 is evaluated 4 days
after enrolment. Patients will be interviewed by tele-
phone using the structured format of the questionnaires
of RMDQ and SF-36.
For patients with persisting pain we will recommend (1)
to continue analgesic therapy and (2) to attend their gen-
eral practitioner for further diagnostic work-up and
treatment.
Adverse events
An adverse event is any event during a clinical study, in-
cluding intercurrent illness or accident, which impairs
the well-being of the subject; it may also take the form of
an abnormal laboratory value. The term adverse event
does not imply a causal relationship with the study treat-
ment.
All subjects experiencing adverse events – whether con-
sidered associated with the use of the study medication
or not – will be monitored until symptoms subside and
any abnormal laboratory values have returned to base-
line, or until there is a satisfactory explanation for the
changes observed, or until death, in which case a full pa-
thologist's report will be supplied, if possible. All find-
ings must be reported on an "Adverse event" page in the
case record form.
Adverse events are divided into the categories "serious"
(fatal, life-threatening, or permanently disbling) and
"nonserious". All adverse events, including intercurrent
illnesses, will be reported and documented.
Data management
We intend to transfer data from case record forms to the
computer database (MS Excel 97) by two investigators in
duplicate and independently. Data will be compared and
inconsistencies will be sorted out by referring to the orig-
inal case record form. If there are still range, consistency
or plausibility problems, the patient chart will be as-
sessed. If after these measures values are still implausi-
ble or missing we intend to treat them as missing data.
We do not intend to substitute these data with e.g. aver-
age values. We plan to assess whether missing data, par-
ticularly core data, may introduce bias by sensitivity
analysis.
Confidentiality
Upon entry into the trial each patient will receive a
unique identifying number. Subsequently only this
number will be used in the case record forms and the in-
vestigator responsible for data management is not aware
of the patients' identity nor treatment allocation. The pa-
tient's identity is only known to the treating physician
and those investigators who are responsible for follow-
up management. These investigators are however not in
the possession of any other confidential information.
Abbreviations
RMDQ Roland Morris disability questionnaire
SF-36 Short Form 36 health survey questionnaire
VAS Visual Analogue Scale
ED Emergency Department
HIV Human Immuno-deficiency Virus
NSA Non-Steroidal Analgesics
Competings interests
None of the investigators will earn in any possible way by
the conduct of this trial and more importantly, analysis,
interpretation and publication of the data will be per-
formed independently by the investigators and will not
be influenced by the pharmaceutical industry.
There are no other competing interests.
Acknowledgements
We submitted the protocol to the "Medizinisch-Wissenschaftlicher Fonds 
des Bürgermeisters der Bundeshauptstadt Wien". Up to now (17.10.01) 
there is no decision.
NOVARTIS Pharma GmbH will support the study by providing the patient 
insurance.
NOVARTIS Pharma GmbH will not be involved in data collection, analysis 
or data interpretation.
We are grateful to Dr.Martin Schillinger for generating the random se-
quence.
References
1. Statistisches Zentralamt: Gesundheitsbericht der Stadt Wien
2000 [Health report of Vienna 2000]. Vienna 2000
2. Deyo RA, Weinstein JN: Low back pain.  N Engl J Med 2001,
344:363-370
3. van Tulder MW, Scholten RJPM, Koes BW, Deyo RA: Non steroidal
anti-inflammatory drugs for low back pain (Cochrane Rev)
The Cochrane Library 2000, issue 4.:
4. Torgerson D, Sibbald B: Understanding controlled trials: What
is a patient preference trial? BMJ 1998, 316:360BMC Emergency Medicine 2001, 1:2 http://www.biomedcentral.com/1471-227X/1/2
5. Bur A, Müllner M, Sterz F, Hirschl MM, Laggner AN: The emergen-
cy department in a 2000-bed teaching hospital: saving open
ward and intensive care facilities. European Journal of Emergency
Medicine 1997, 4:19-33
6. Kendrick D, Fielding K, Bentley E, Kerslake R, Miller P, Pringle M: Ra-
diography of the lumbar spine in primary care patients with
low back pain: a randomised controlled trial.  BMJ 2001,
322:400-405
7. Hellmann DB, Stone JH: Arthritis and musculoskeletal disor-
ders. In: Current medical diagnosis and treatment. Tierney LM, McPhee SJ,
Papadakis MA (eds). McGraw Hill New York 40th edition 2001825
8. Carlsson AM: Assessment of chronic pain I. Aspects of the re-
liability and validity of the visual analogue scale. Pain 1983,
176:87-101
9. Wiesinger GF, Nuhr M, Quittan M, Ebenbichler G, Wölfl G, Fialka-
Moser V: Cross-cultural adaptation of the Roland-Morris
questionnaire for German-speaking patients with low back
pain. Spine 1999, 24:1099-1103
10. Bullinger M, Kirchberger I, Ware J: Der deutsche SF-36 Health
Survey. Zf Gesundheitswiss 1995, 3:21-36
11. Babej-Dölle R, Freytag S, Eckmeyer J, Zerle G, Schinzel S, Schmieder
G, Stankov G: Parenteral dipyrone versus diclophenac and pla-
cebo in patients with acute lumbago or sciatic pain: Rand-
omized observer-blind mnlticenter study. Int J Clin Pharmacology
1994, 32:204-209
12. Machin D, Campbell MJ: Sample size tables for clinical trials.
Blackwell Science, UK 1997
13. Altman DG, Bland MJ: How to randomise. BMJ 1999, 319:703-704
14. Roland M, Morris R: A study of the natural history of low back
pain. Part I: development of a reliable and sensitive measure
of disability in low back pain. Spine 1983, 8:141-144
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.com